PTH and endometrial cancer: Estrogen, bisphosphonates, parathyroid hormone (PTH), or selective estrogen receptor modulators (SERMs) has been used to prevent the postmenopausal bone loss [5], but many evidences indicate that long-term treatments with those drugs might cause adverse reactions, such as an increased risk of ovarian and endometrial cancer [6,7,8,9], osteonecrosis of the jaws [10], nervous system disorders [11], venous thromboembolism [12], etc. Thus, an alternative therapeutic strategy with a proven efficacy should be developed to prevent and treat osteoporosis.